Agentix Corp. (AGTX) company profile
Close on Oct 16, 2026Market cap $801.34KP/E –Yield –
About Agentix
Biological Products, (No Diagnostic Substances), SIC 2836
Agentix Corp. is a clinical-stage biopharmaceutical company that focuses on developing treatments for metabolic disorders, including type 2 diabetes, obesity, and fatty liver disease. The company's therapeutic pipeline centers on peripherally-restricted cannabinoid type 1 receptor antagonists and inverse agonists designed not to cross the blood-brain barrier. Its primary product candidates include AGTX-2004, a CB1 receptor antagonist advancing toward human clinical trials, and AGTX-2003, an inverse agonist undergoing preclinical evaluation. Because its drug candidates remain in development without commercial sales, the firm has no commercial customers, though it aims to partner with larger pharmaceutical corporations.
The company manages development activities through an operational subsidiary, Agentix Australia Pty Ltd, located in Australia. It maintains no full-time or part-time employees, with corporate affairs overseen by a director. Agentix does not rent or own physical real estate or facilities, maintaining its corporate headquarters at a virtual office address in Dana Point, California.
Summary of the business section of Agentix's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Agentix Corp.
- Founded
- 2013
- Headquarters
- Dana Point, CA
- Address
- 32932 Pacific Coast Highway, #14-254 92629
- Phone
- (321) 229-2014
- Website
- agentixcorp.com
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Nevada
- Fiscal year ends
- March 31
- Auditor
- Fruci & Associates II, PLLC, Spokane, Washington
Stock & identifiers
- Ticker
- AGTX
- Exchange
- OTC
- IPO date
- Aug 21, 2015
- Shares outstanding
- 40M, Aug 7, 2026
- Public float
- $1.33M, Sep 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Stock splits
- 100-for-1, Feb 25, 2020; 1-for-537 reverse, Jul 15, 2019; 1-for-1000 reverse, Jul 3, 2019
- SEC CIK
- 1603345
- FIGI
- BBG0068Q8V76
- Share class FIGI
- BBG0068Q8V85
- EIN
- 46-2876282
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
No recent ownership filings by officers or directors
Agentix's leadership is listed in its proxy statement (Form DEF 14A).
Corporate history
Events identified from SEC filings
See a number that looks wrong?